ModifiedUnitedHealthcarePolicy CSNCT 0 379.02

Respiratory Pathogen Nucleic Acid Detection Testing (for North Carolina Only)

Medical policy governing respiratory pathogen nucleic acid detection (multiplex panels and mNGS) in North Carolina; applies to outpatient testing and ordering providers covered by UnitedHealthcare in NC.

Policy Summary

PayerUnitedHealthcare

PolicyRespiratory Pathogen Nucleic Acid Detection Testing (for North Carolina Only)

Policy CodePolicy CSNCT 0 379.02

Change TypeClarified not medically necessary stanceevidence and references updated

Effective DateMay 1, 2026

Next Review Date

Key ActionDo not seek prior authorization for outpatient respiratory multiplex panels with six or more targets because these are designated not medically necessary and are unlikely to be approved.

SourceLink

POLICY UPDATE CHANGES

Respiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary.

Added reference link to the Reimbursement Policy titled Laboratory Services Policy, Professional.

Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information.

Archived previous policy version CSNCT3791.01.

>=6panel threshold

May 1, 2026effective

NCjurisdiction

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

Not medically necessary: Outpatient multiplex panels (>=6 targets)

Not medically necessary when ALL of the following are met:

Outpatient multiplex panel rule: Respiratory pathogen panel testing of six or more targets in an outpatient setting is considered unproven and not medically necessary due to insufficient evidence of efficacy for all indications.>= 6 targets

Policy applies to North Carolina outpatient setting.

Codes shown in the policy are provided for reference and do not by themselves guarantee coverage or reimbursement. Several proprietary panel codes are listed in the Applicable Codes section (for example, 0115U, 0225U, 0556U, 0563U, 0564U). Codes marked with an asterisk (*) are not on the State of North Carolina Medicaid Fee Schedule and therefore may not be covered by NC Medicaid. Inclusion of a code in this policy does not imply that the service is a covered benefit under a specific member plan; benefit coverage is determined by the member-specific benefit plan document and applicable laws.

For average-risk or otherwise relatively healthy outpatients, the policy aligns with guideline-based diagnostic stewardship: routine outpatient nucleic acid–based testing for respiratory viral pathogens other than influenza is not recommended. The American Thoracic Society issues a conditional recommendation, based on very low–quality evidence, against routine outpatient testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia. The ASM guidance similarly notes limited outcome-based evidence supporting routine testing of adult outpatients for viruses other than influenza and highlights that testing priorities should reflect patient risk and care setting.

Respiratory pathogen panel testing that includes six or more targets (>= 6 targets) when performed in the outpatient setting is considered unproven and not medically necessary due to insufficient evidence of efficacy across indications. This determination applies to outpatient use in North Carolina and is the basis for limiting coverage of large multiplex panels for routine outpatient evaluation.

Clinical guidance and evidence syntheses emphasize selective use of broad multiplex testing. For adults with suspected community-acquired pneumonia, the ATS guidance suggests against routine outpatient testing for noninfluenza viral pathogens (conditional recommendation; very low–quality evidence). The ASM guidance similarly recommends targeting multiplex respiratory testing to higher-risk populations and cautions that routine testing of adult outpatients for noninfluenza viruses may not provide demonstrable outcome benefits.

Indications Where Testing May Be Appropriate

Inpatient or complex cases where mNGS or multiplex testing may be useful (e.g., immunocompromised patients or when conventional tests fail).

Covered when ANY of the following contextual conditions apply (inpatient or complex clinical situations):

Situations where mNGS or multiplex testing may be useful

When conventional diagnostic tests have failed to identify a pathogen and further pathogen identification is needed to guide management (e.g., unexplained severe infection).
mNGS may be considered when conventional tests fail; evidence promising but limited.
In immunocompromised patients where broad, rapid pathogen detection could change clinical care or exclude infection (e.g., negative conventional testing but high clinical suspicion).
mNGS has high value for ruling out infection in immunocompromised individuals per meta-analysis.
When comprehensive pathogen detection is required to guide urgent clinical decisions in complex hospitalized patients (e.g., severe pulmonary infection with unknown etiology).

Coding and Test Identifiers

Example multiplex panel codesmixed

0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0556U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected.
0563U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 11 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.
0564U	Infectious disease (bacterial and/or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 10 viral targets and 4 bacterial targets, qualitative RT-PCR, upper respiratory specimen, each pathogen reported as positive or negative.

inv-07: Panel target count threshold

Panel target count threshold>= 6 targets

Policy stanceRespiratory pathogen panel testing of six or more targets in an outpatient setting is unproven and not medically necessary.

Applicable settingOutpatient (North Carolina)

Provider Requirements, Prior Authorization, and Documentation

Denial Risk

Prior Authorization: Outpatient multiplex panels (≥6 targets)

Outpatient respiratory multiplex panels that detect six or more targets are considered not medically necessary and may be denied. Providers should obtain prior authorization when required by the member's benefit plan before ordering these large multiplex outpatient respiratory panels to avoid coverage denial or claim payment issues.

Affected tests: multiplex respiratory pathogen panels with ≥6 targets (see applicable proprietary codes: 0115U, 0225U, 0556U, 0563U, 0564U).
Action: Verify benefit plan prior authorization requirements before ordering; if PA is required and not obtained, services may be denied.
Denial risk: Outpatient panels ≥6 targets — considered unproven/not medically necessary.

Prior Authorization

Prior Authorization Not Specified

This policy section does not specify particular CPT or HCPCS codes that universally require prior authorization. Prior authorization requirements, if any, are determined by the member's specific benefit plan and applicable federal or state contractual requirements.

Who Should Order and When

Note

Ordering requirements — provider type not restricted

No provider-type ordering restrictions are specified in this portion of the policy; the evidence and referenced studies include testing performed in outpatient clinics, urgent care, and emergency department settings.

No explicit restriction on which provider types may order tests is stated
Referenced studies include outpatient clinic settings

Note

Ordering requirements — prioritize high‑risk or hospitalized patients

Testing priorities vary by clinical setting; high‑risk or hospitalized patients (e.g., ICU, transplant, hematology/oncology, select pediatric patients) should be prioritized for multiplex testing, while routine testing of average/low‑risk outpatients for non‑influenza viruses is not recommended.

Prioritize hospitalized, ICU, transplant, hematology/oncology, and pediatric patients with underlying illness
Routine outpatient testing for non‑influenza viruses in otherwise healthy patients is discouraged

Frequency and Repeat Testing Limits

inv-23: Not specified in this portion of the policy (frequency limits)

Frequency limitsNot specified in this portion of the policy.

Coding noteListing of codes does not imply coverage; benefit determined by member plan.

NC Medicaid noteCodes marked with an asterisk may not be on the NC Medicaid Fee Schedule and may not be covered.

inv-24: None specified in this document portion (frequency limits)

Frequency limitsNone specified in this document portion.

Use guidanceDiagnostic stewardship recommended to limit use in relatively healthy outpatients.

Services and Tests Not Covered

Outpatient respiratory pathogen panel testing that includes six or more targets (>= 6 targets) is designated as not covered / not medically necessary for outpatient settings due to insufficient evidence supporting clinical benefit.

Routine testing of otherwise healthy outpatients for noninfluenza respiratory viruses is of questionable benefit and may be limited. Guideline recommendations and review articles advise against routine outpatient multiplex testing for viruses other than influenza in average-risk adult outpatients and suggest prioritizing testing for higher-risk or hospitalized populations.

Background and Technology Overview

Molecular assays (including RT‑PCR and other nucleic acid amplification tests and metagenomic sequencing) detect microbial nucleic acid in respiratory specimens, but detection of nucleic acid does not necessarily indicate viable organism, active replication, or clinical disease. Large multiplex panels can identify multiple organisms and prolonged shedding, producing results that may be difficult to interpret in the outpatient context; this contributes to the policy position that broad outpatient panels (>= 6 targets) are unproven for routine outpatient care.

Key Definitions

inv-17: Metagenomic next-generation sequencing (mNGS) definition

DefinitionComprehensive detection of all genes from all organisms within a sample to identify pathogenic microbes by comparing nucleic acid sequences.

ScopeDetects bacterial, fungal, parasitic, and viral genetic material from a single tissue or liquid specimen.

LimitationsDetection does not confirm a viable organism or ongoing replication.

inv-18: Multiplex RT-PCR panel definition

DefinitionPredefined assay that identifies multiple viral and/or bacterial nucleic acids simultaneously in respiratory specimens, reporting each analyte as detected or not detected.

MethodReverse transcription - polymerase chain reaction (RT-PCR) and other nucleic acid amplification techniques.